Statin use is associated with improved prostate cancer survival: Is it time for a clinical trial?

Expert Review of Anticancer Therapy

Volumn 10, Issue 10, 2010, Pages 1563-1567

  Murtola, Teemu J ^a,b  

^a Central Finland Central Hospital   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

Author keywords

biochemical outcome; HMG CoA reductase inhibitors; progression; proliferation; prostate cancer; statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; PROSTATE SPECIFIC ANTIGEN; ROSUVASTATIN; SIMVASTATIN;

BRACHYTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; NOTE; PROSTATE ADENOCARCINOMA;

EID: 77958055165     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.137     Document Type: Note

References (36)

1. Carroll MD, Lacher DA, Sorlie PD et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 294(14), 1773-1781 (2005).
2. Ray KK, Seshasai SR, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch. Intern. Med. 170(12), 1024-1031 (2010).
3. Chatzizisis YS, Koskinas KC, Misirli G et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 33(3), 171-187 (2010).
4. Clarke PM, Fitzgerald EM. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Med. J. Aust. 192(11), 633-636 (2010).
5. Jackson SM, Ericsson J, Edwards PA. Signaling molecules derived from the cholesterol biosynthetic pathway. Subcell. Biochem. 28, 1-21 (1997).
6. Platz EA, Leitzmann MF, Visvanathan K et al. Statin drugs and risk of advanced prostate cancer. J. Natl Cancer Inst. 98(24), 1819-1825 (2006).
7. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol. Biomarkers Prev. 16(11), 2213-2217 (2007).
8. Flick ED, Habel LA, Chan KA et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol. Biomarkers Prev. 16(11), 2218-2225 (2007).
9. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 16(11), 2226-2232 (2007). (Pubitemid 351196353)
10. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol. Drug Saf. 17(1), 27-36 (2008).
11. Murtola TJ, Visakorpi T, Lahtela J, Syvala H, Tammela TL. Statins and prostate cancer prevention: where we are now, and future directions. Nat. Clin. Pract. Urol. 5(7), 376-387 (2008).
12. Brookhart MA, Patrick AR, Dormuth C et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am. J. Epidemiol. 166(3), 348-354 (2007).
13. Murtola TJ, Tammela TL, Maattanen L et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int. J. Cancer 127(7), 1650-1659 (2010).
14. Akduman B, Tandberg DJ, O'Donnell CI, Hughes A, Moyad MA, Crawford ED. Effect of statins on serum prostate-specific antigen levels. Urology DOI: 10.1016/j. urology.2010.03.044 (Epub ahead of print) (2010).
15. Breau RH, Karnes RJ, Jacobson DJ et al. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J. Urol. 184(2), 494-500 (2010).
16. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J. Natl Cancer Inst. 100(21), 1511-1518 (2008).
17. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J. Urol. 173(6), 1923-1925 (2005).
18. Murtola TJ, Pennanen P, Syvala H, Blauer M, Ylikomi T, Tammela TL. Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate 69(9), 1017-1023 (2009).
19. Krycer JR, Kristiana I, Brown AJ. Cholesterol homeostasis in two commonly used human prostate cancer cell-lines, LNCaP and PC-3. PLoS One 4, e8496 (2009).
20. Zadra G, Priolo C, Patnaik A, Loda M. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin. Cancer Res. 16(13), 3322-3328 (2010).
21. Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol. Cell Endocrinol. 295, 115-120 (2008).
22. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J. Clin. Oncol. 28, 2653-2659 (2010).
23. Kollmeier MA, Katz MS, Mak K et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp.2009.12. 006 (2010) (Epub ahead of print).
24. Soto DE, Daignault S, Sandler HM, Ray ME. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 73, 158-162 (2009).
25. Moyad MA, Merrick GS, Butler WM et al. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol. Nurs. 26, 298-303 (2006).
26. Hamilton RJ, Banez LL, Aronson WJ et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116(14), 3389-3398 (2010).
27. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control 21, 61-68 (2010).
28. Magura L, Blanchard R, Hope B, Beal JR, Schwartz GG, Sahmoun AE Hypercholesterolemia and prostate cancer: a hospital-based case-control study Cancer Causes Control 19, 1259-1266 (2008).
29. Di Vizio D, Solomon KR, Freeman MR. Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori 94, 633-639 (2008).
30. Leon CG, Locke JA, Adomat HH et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 70, 390-400 (2010).
31. Nguyen PL, Chen MH, Catalona WJ et al. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer: implications for management. Cancer 113, 3146-3152 (2008).
32. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 101, 3628-3634 (2003).
33. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother. Pharmacol. 57, 155-164 (2006).
34. Thibault A, Samid D, Tompkins AC et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 2, 483-491 (1996).
35. Garwood ER, Kumar AS, Baehner FL et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat. 119, 137-144 (2010).
36. Berney DM. Biomarkers for prostate cancer detection and progression: beyond prostate-specific antigen. Drug News Perspect. 23, 185-194 (2010).